A 10-year review of presentation, management and outcomes of STEMI in a high-volume regional tertiary Australian centre

• Published in: International journal of cardiology 2024-09, Vol.410, p.132224, Article 132224
• Main Authors: Tierney, M., Norman, S., Al Ahmad, J., Hansen, T., Lee, A., Shetty, P.
• Format: Article
• Language: English
• Subjects: PCI; Regional cardiology; STEMI
• ISSN: 0167-5273; 1874-1754; 1874-1754
• DOI: 10.1016/j.ijcard.2024.132224

To assess the trends and impact of changes in management of ST Elevation Myocardial Infarction (STEMI) from 2010 to 2019. Retrospective analysis of data from STEMI hospitalisations including demographic, comorbidity, angiographic and outcome data. High-volume non-surgical regional Australian tertiary referral centre. Index & 12-month mortality (all-cause & cardiovascular), door-to-balloon time, target-vessel failure, target-vessel revascularisation & procedure-related bleeding. From 2010 to 2019, 1299 patients presented with STEMI. The cardiovascular risk factor profile did not significantly change over the 10-year study period, p = 0.23. There was a significant trend toward culprit vessel percutaneous coronary intervention with stenting, rather than balloon angioplasty followed by surgical revascularisation, p = 0.029. The mean door-to-balloon time was 88 +/− 5.7 min and demonstrated a statistically significant improvement across the decade, p = 0.035. Radial access became the preferred angiographic approach (2010 92% femoral, 2019 91% radial). Drug-eluting stents (DES) replaced bare metal stent use. There was a statistically significant reduction in 12-month cardiovascular mortality across the decade (p = 0.042). However index hospitalisation (cardiovascular and all-cause) and 12-month all-cause mortality did not reduce. Young patients and women are important sub-groups of STEMI presentations with different risk factor profile. Advances in management of STEMI such as radial access, use of DES and a significant reduction in door-to-balloon time across the decade resulted in a reduction of 12-month cardiovascular mortality over the decade however there was no significant reduction in 12-month all-cause mortality, or index hospitalisation cardiovascular or index hospitalisation all-cause mortality. Further research is needed to ensure non-mortality outcomes, such as heart failure hospitalisation and quality of life, also demonstrate temporal improvement with STEMI management advances. Earlier cardiovascular risk assessment should be considered in smokers than is currently recommended in Australian guidelines (≥45yo for most individuals). •The known: The management of ST Elevation Myocardial Infarction (STEMI) has evolved with advances in acute management, stent design and secondary prevention.•The new: Advances in the management of STEMI including Drug Eluting Stents, radial angiography and a reduction in door-to-balloon time resulted in a statistically sig